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CAN YOU DIAGNOSE ME NOW? A PROPOSAL TO MODIFY
THE FDA’S REGULATION OF SMARTPHONE MOBILE
HEALTH APPLICATIONS WITH A PRE-MARKET
NOTIFICATION AND APPLICATION DATABASE PROGRAM
Stephen McInerney*
Advances in mobile technology continually create new possibilities for the future of
medical care. Yet these changes have also created concerns about patient safety.
Under the Food, Drug, and Cosmetic Act, the Food and Drug Administration
(FDA) has the authority to regulate a broad spectrum of products beyond tradi-
tional medical devices like stethoscopes or pacemakers. The regulatory question is
not if the FDA has the statutory authority to regulate health-related software, but
rather how it will exercise its regulatory authority. In September 2013, the FDA
published Final Guidance on Mobile Medical Applications; in it, the Agency lim-
ited its oversight to a small subset of medical-related mobile applications, referred to
as “mobile medical applications.” For the Final Guidance to be effective, the FDA
must continue to work directly with all actors—including innovators, doctors, and
patients as the market for mobile health applications continues to develop. This
Note argues that the FDA should adopt a two-step plan—a pre-market notification
program and a mobile medical application database—to aid in the successful im-
plementation of its 2013 Final Guidance. By doing so, the FDA will ensure that
this burgeoning market can reach its fullest potential.
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INTRODUCTION
After being told by her local doctor that she simply suffered from
anxiety, Mary was at a loss as to why she still felt sick.1 Traditionally,
Mary’s only option would be to seek a second opinion from another
physician. Instead, she turned to a mobile application: HealthTap+.
Mary spent two hours on HealthTap+, at which point a doctor who
contributed to the site suggested her condition may be a blocked
artery.2 She soon saw a cardiology specialist, who confirmed the di-
agnosis and inserted a coronary stent, which may have saved Mary’s
life.3
Mary’s story is not unique. More and more people turn to their
smartphones and medical-related applications, or mobile health ap-
plications for medical advice. The use of mobile health applications
is revolutionizing healthcare delivery, both helping doctors treat
patients outside of traditional healthcare settings and helping con-
sumers manage their own health. A recent survey of the mobile
application market shows at least 40,000 available medical-related
apps, with a market size in 2013 estimated at $6.3 billion.4 By 2018,
the market size is projected to grow to a staggering $20.7 billion.5
Mobile health applications vary widely in terms of scope and
functionality: some are simply medical dictionaries, allowing users
to understand health-related terminology,6 while others perform a
more complex task for the user, such as scanning over-the-counter
drug bar codes to check for medication interactions.7 These appli-
cations also target different consumers. Some applications are
1. Amy O’Leary, An App That Saved 10,000 Lives, N.Y. TIMES (Oct. 5, 2013), http://
bits.blogs.nytimes.com/2013/10/05/how-to-save-10000-lives-with-an-app-flatter-doctors/.
The name “Mary” is used solely for the purposes of this Note.
2. Id.
3. See id.
4. Scott Rupp, Mobile Health Apps and Solutions Market Worth $20.7 Billion by 2018, ELEC-
TRONIC HEALTH REP. (Dec. 11, 2013), http://electronichealthreporter.com/hit-news/mobile-
health-apps-and-solutions-market-worth-20-7-billion-by-2018/; Jenny Gold, FDA Regulators Face
Daunting Task as Health Apps Multiply, USA TODAY (June 27, 2012), http://usatoday30.usa
today.com/news/health/story/2012-06-22/health-apps-regulation/55766260/1.
5. Rupp, supra note 4.
6. See, e.g., Taber’s Medical Dictionary with Updates, ITUNES, https://itunes.apple.com/us/
app/tabers-medical-dictionary/id301866347?mt=8 (last visited Mar. 20, 2015).
7. See, e.g., Pharmacy On the Go, CVS PHARMACY, http://www.cvs.com/promo/promo-
LandingTemplate.jsp?promoLandingId=mobile-pharmacy (last visited Mar. 20, 2015).
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geared towards the general public,8 some specifically to doctors,9
and others to both.10 The variety and complexity among these types
of applications—which can operate on multiple mobile devices,
from iPhones or Androids to iPad tablets—highlight the difficulties
involved in regulating mobile applications.
Due in part to the novelty of the field and in part to the difficulty
of promulgating regulations in general, the federal government has
not typically regulated mobile apps. In September 2013, in re-
sponse to confusion among application developers over regulation
of mobile apps, the Food and Drug Administration (FDA or the
Agency) published its Final Guidance for Mobile Medical Applica-
tions to explain its plans to regulate this quickly evolving industry.11
Under the Food, Drug, and Cosmetic Act (FDCA or the Act), the
FDA has the statutory authority to regulate “medical devices,”12 a
term that is broadly defined and includes “mobile medical applica-
tions.”13 The Final Guidance explained that the FDA will regulate
mobile applications with a soft touch, limiting its regulatory over-
sight to “only those mobile apps that [qualify as] medical devices
and whose functionality could pose a risk to a patient’s safety if
the mobile app were to not function as intended.”14 The FDA
termed this subset of mobile health applications “mobile medi-
cal applications.”15 Ultimately, the FDA is expected to actively
8. See, e.g., Experience WebMD on the Go Via Your Smartphone or Tablet, WEBMD, http://
www.webmd.com/mobile (last visited Mar. 20, 2015) (providing users with an interactive tool
to check their symptoms, access drug and treatment information, get first aid tips and check
local health listing).
9. See, e.g., Doximity–Physician Network, ITUNES, https://itunes.apple.com/us/app/dox-
imity-physician-network/id393642611?mt=8 (last visited Mar. 20, 2015) (providing healthcare
professionals with a tool for HIPAA-secure communication and electronic faxing).
10. See, e.g., ASTHMAMD, http://www.asthmamd.org (last visited Mar.20, 2015) (allowing
users to track their asthma activity and share these activities with their physicians to be in-
cluded in their medical records).
11. U.S. FOOD & DRUG ADMIN., MOBILE MEDICAL APPLICATIONS: GUIDANCE FOR INDUSTRY
AND FOOD AND DRUG ADMINISTRATION STAFF (2013), available at http://www.fda.gov/
downloads/MedicalDevices/. . ./UCM263366.pdf [hereinafter FINAL GUIDANCE].
12. See 21 U.S.C. § 321(h) (2012).
13. See infra text accompanying note 15.
14. FINAL GUIDANCE, supra note 11, at 13 (emphasis added).
15. See id. “Medical mobile application” (or “medical mobile app”) is a term of art within
the Final Guidance to describe applications that the FDA has determined qualify for regula-
tion under its “medical device” regulatory authority. This is not to be confused with the term
“medical health application” (or “medical health app”) used throughout this Note as a ge-
neric term for any mobile device application that serves a medical or health related function,
irrespective of whether the application would qualify for regulation under the FDA’s “medi-
cal device” regulatory authority.
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regulate less than twenty percent of all mobile health applica-
tions.16
The public response to the FDA’s Final Guidance has been
mixed. Many experts have lauded the FDA’s restrained regulatory
approach.17 Others, however, argue that the rule is still too restric-
tive on application developers.18 In February 2014, Senators Marco
Rubio (R-Fla.), Deb Fischer (R-Neb.), and Angus King (I-Maine)
proposed the Preventing Regulatory Overreach To Enhance Care
Technology (PROTECT) Act19 to limit the FDA’s regulatory author-
ity over mobile health applications and to assign oversight of many
applications to the National Institute of Standards and Technology
(NIST), an agency without regulatory authority.20 More specifically,
NIST does not have authorization to actively regulate applications,
and would not have the subpoena power necessary to investigate
wrongdoing for any non-medical software or to criminally enforce
existing regulations.21 Thus, even after the FDA issued its 2013 Final
Guidance, policy makers continue to disagree as to the proper reg-
ulatory approach for mobile health applications.
This Note argues that although the 2013 Final Guidance is a
good first step in balancing innovation and protecting users from
unsafe mobile health applications, to aid in the successful imple-
mentation of the Final Guidance the FDA should adopt a two-
16. Happtique Announces Inaugural Class of Certified Health Apps, PR NEWSWIRE (Dec. 2,
2013), http://www.prnewswire.com/news-releases/happtique-announces-inaugural-class-of-
certified -health-apps-234063701.html.
17. See, e.g., Christina Farr, Congress Wants to Kick the FDA Out of Digital Health with this
New Bill, VENTUREBEAT (Feb. 26, 2014), http://venturebeat.com/014/02/26/new-digital-
health-bill-proposes-to-undermine-the-fda-draws-mixed-reactions/ (“The September [FDA Fi-
nal Guidance] was greeted with relief and fanfare . . .”).
18. See, e.g., Alison Diana, Will Most Healthcare Apps Escape FDA Scrutiny?, INFO. WEEK
(Feb. 13, 2014), http://www.informationweek.com/healthcare/policy-and-regulation/will-
most-healthcare-apps-escape-fda-scrutiny/d/d-id/1113812.
19. In the House of Representatives, Representative Marsha Blackburn (R-Tenn.) pro-
posed similar legislation titled the SOFTWARE Act (H.R. 3303). See Press Release, King,
Fischer Introduce Legislation to Protect Jobs, Prevent Overregulation in Growing Health IT
Industry (Feb. 10, 2014), available at http://www.king.senate.gov/newsroom/press-releases/
king-fischer-introduce-legislation-to-protect-jobs-prevent-overregulation-in-growing-health-it-
industry.
20. See Farr, supra note 17; Press Release, King, Fischer Introduce Legislation to Protect
Jobs, supra note 19.
21. Under the PROTECT Act, the FDA would retain authority over “medical software.”
See Stephanie Zeppa & Lauren Lewis, Mobile Medical App Regulations on the Move —Proposed
Bills to Further Alter the Regulatory Landscape of Mobile Medical Applications, SHEPPARD MULLIN
HEALTHCARE L. BLOG (Mar. 31, 2014), http://www.sheppardhealthlaw.com/2014/03/arti-
cles/other/mobile-medical-app-regulations-on-the-move-proposed-bills-to-further-alter-the-
regulatory-landscape-of-mobile-medical-applications/; Farr, supra note 17 (“We are extremely
concerned that this bill will deregulate a broad swath of medical devices that rely on software
and will create opportunities for rampant ‘gaming’ to avoid regulation.”).
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pronged approach: (1) a pre-market notification program and (2)
a mobile medical application database. The argument will proceed
as follows: Part I will examine the breadth of the mobile health ap-
plication market and explain that in order to be effective, the FDA’s
regulatory scheme must be able to adjust to an ever-changing mar-
ket. This ability to evolve is essential to balance consumer safety and
innovation. Part II will demonstrate that the FDCA provides clear
statutory authority for the FDA to regulate a wide range of mobile
health applications. Part III will contend that, while the 2013 FDA
Final Guidance is a step in the right direction, it leaves both the
FDA and application developers with minimal ability to anticipate
future regulatory changes. Finally, Part IV will argue that imple-
menting a pre-market notification program and a mobile medical
application database would remove current and future uncertainty
and better address safety concerns in this emerging market.
I. MOBILE HEALTH APPLICATIONS
Since the Ericsson GS88 launched in 1997,22 smartphones have
developed far beyond simple telephonic functions and transformed
into handheld computers. The first smartphones combined the
functions of a personal digital assistant (PDA) with a mobile
phone.23 For example, smartphones were equipped with calendars,
lists, and other task-oriented applications.24 “Later models added
the functionality of portable media players, low-end compact digital
cameras, pocket video cameras, and GPS navigation [systems] to
form one [unified] multi-use device.”25
The true advent of mobile applications (“applications” or “apps,”
as they are known today) did not occur until shortly after Apple
Inc. developed the iPhone in 2007.26 That summer, instead of re-
stricting iPhone application development to its own in-house
developers, Apple opened the floodgates for anyone—from a multi-
22. History, STOCKHOLM SMARTPHONE, http://www.stockholmsmartphone.org/history/
(last visited Mar. 20, 2015).
23. See Horace Dediu, The parable of the PDA: predicting the smartphone’s future, ASYMCO
(Dec. 27, 2010), http://www.asymco.com/2010/12/27/the-parable-of-the-the-pda-predict-
ing-the-smartphones-future/.
24. See id.
25. Smartphone, MASHABLE, http://mashable.com/category/smartphone/ (last visited
Mar. 20, 2015).
26. See Alex Krouse, iPads, iPhones, Androids, and Smartphones: FDA Regulation of Mobile
Phone Applications as Medical Devices, 9 IND. HEALTH L. REV. 731, 734 (2012); Press Release,
Apple Inc., iPhone to Support Third-Party Web 2.0 Applications (June 11, 2007), available at
http://www.apple.com/pr/library/2007/06/11iPhone-to-Support-Third-Party-Web-2-0-Ap-
plications.html.
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billion dollar company to a teenager in her parents’ basement—to
create a mobile application.27 This shift led to the previously
unimaginable proliferation of applications that exists in the market-
place today.28 Within the first year, Apple’s “App Store” offered
50,000 iPhone applications.29 That number increased to 225,000 in
2010, and as of October 2014 is over 1.3 million.30 Similarly, the
App Store’s main competitor, Google’s Android Market, offers
many similar applications for Android smartphones. Today, the An-
droid Market offers over 1.5 million mobile applications.31
A. The Mobile Health Application Paradox
Mobile health applications present a difficult regulatory di-
lemma. On the one hand, by increasing the amount of health
information available to consumers, these applications can help pa-
tients take control of their health and improve the delivery of
medical care. For example, the University of Cambridge recently
developed an application, Colorimetrix, which allows physicians to
remotely monitor their patient’s conditions, including diabetes,
kidney disease, and urinary tract infections.32 After the patient uses
a urine test strip, the application—not the physician—instantly ana-
lyzes a picture of the strip and generates a medical report.33
Subsequently, this medical report and diagnosis can be emailed to a
doctor for any necessary prescriptions.34 Applications like
Colorimetrix provide an especially useful service for patients in re-
mote areas, where access to physicians is limited and patients may
not otherwise receive such treatment.35
27. See Press Release, Apple Inc., supra note 26.
28. See Krouse, supra note 26, at 733–35 (tracing the history of mobile applications and
attributing the increase in mobile apps to a rise in mobile device usage and the development
of online app stores).
29. See Sam Costello, How Many Apps Are in the iPhone App Store, ABOUT.COM, http://
ipod.about.com/od/iphonesoftwareterms/qt/apps-in-app-store.htm (last visited Mar. 20,
2015).
30. Id.
31. Number of Available Android Applications, APPBRAIN, http://www.appbrain.com/stats/
number-of-android-apps (last visited Mar. 20, 2015).
32. Mihir Patkar, New Camera-Centric Smartphone App Puts Healthcare in Your Pocket, THE
DAILY BEAST (Mar. 28, 2014), http://www.thedailybeast.com/articles/2014/03/28/new-cam-
era-centric-smartphone-app-puts-health-care-in-your-pocket.html.
33. Id. Although reviewed by a physician, the application still plays a vital role in analyz-
ing the urine strip and generating a medical report for the physician to utilize.
34. Id.
35. See Darrell West, How Mobile Devices are Transforming Healthcare, ISSUES IN TECH. INNO-
VATION, May 2012, at 1, 8, available at http://www.insidepolitics.org/brookingsreports/
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However, these benefits also come with risks. Users who rely on
applications to partially or completely replace a professional physi-
cian may receive substandard treatment as a result. First, the
application may issue an inaccurate diagnosis. For example, the
iTunes application store is flooded with skin cancer diagnostic ap-
plications36 that promise to “save your life!”37 The majority of these
applications are relatively inexpensive because they rely on a mathe-
matical algorithm based on self-evaluation (without a clinician) to
alert the user of a skin cancer “diagnosis.”38 In a 2013 Journal of the
American Medical Association (JAMA) study, a group of University
of Pittsburgh dermatologists found that “three out of four
smartphone applications incorrectly classified 30 percent or more
of melanomas as unconcerning.”39 The study concluded that, “reli-
ance on these applications, which are not subject to regulatory
oversight, in lieu of medical consultation can delay the diagnosis of
melanoma and harm users.”40
Second, heavy reliance on medical diagnosis from mobile medi-
cal applications removes the possibility of secondary diagnoses.
When a patient goes to see a physician for an ailment, the physician
examines the patient’s overall health, including temperature, blood
pressure, and other routine tests of vital signs.41 It is not difficult to
imagine a situation where a patient goes to the physician for one
ailment and leaves with a diagnosis for a second ailment lurking
behind the same symptoms.  A doctor would readily consider that
second ailment, but a mobile app would necessarily miss it. Because
mobile apps focus on a particular set of symptoms they may allow
ailments to go undetected and undiagnosed.42
mobile_health_52212.pdf (“Digital technology allows people to overcome the limitations of
geography in health care and access information at a distance.”).
36. See, e.g., Skin Prevention – Photo Body Map for Melanoma and Skin Cancer early detection,
ITUNES, https://itunes.apple.com/us/app/skin-prevention-photo-body/id366657886?mt=8
(last visited Mar. 20, 2015).
37. See id.
38. See Iyatomi Hitoshi et al., An Improved Internet-based Melanoma Screening System with
Dermatologist-like Tumor Area Extracting Algorithm, 32 COMPUTERIZED MED. IMAGING & GRAPHICS
566 (2008).
39. Joel A. Wolf et al., Diagnostic Inaccuracy of Smartphone Applications for Melanoma Detec-
tion, 149.4 JAMA DERMATOL. 422, 422 (2013).
40. Id.
41. See, e.g., Medical Assistants: Taking the 6 Vital Signs, EVEREST COLL., http://medi-
calassistant.everestcollege.edu/articles/medical-assistants-taking-the-6-vital-signs (last visited
Mar. 20, 2015) (“There are usually six tests you’ll run at the start of every patient visit. They
are: 1. Weight, 2. Temperature, 3. Pulse, 4. Blood Pressure, 5. Respiration, 6. Pain.”)
42. See, e.g., Nathaniel R. Carroll, Mobile Medical App Regulation: Preventing a Pandemic of
“Mobilechondriacs,” 7 ST. LOUIS U.J. HEALTH L. & POL’Y 415, 427 (2014), available at http://
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Today, over ninety percent of Americans have a mobile phone.43
Fifty-six percent of people have smartphones that can utilize the
most current mobile health applications.44 This figure rose from
only nineteen percent just three years ago.45 Further, the percent-
age of the population with constant access to the Internet will
continue to increase. Such “connected” Americans plan to use their
mobile phones to monitor their health: today, according to a survey
by CTIA and Harris Interactive, seventy-eight percent of Americans
are interested in mobile health tools46 and twenty-three percent be-
lieve that mobile health could replace doctor visits entirely.47 By
2015, an estimated 500 million people worldwide will use a mobile
health app.48 This proliferation of use raises two competing con-
cerns with mobile health apps: How can the government (1)
promote increased access to mobile health solutions while (2) pro-
tecting consumers from the serious risks these applications may
present?
B. Low-Risk vs. Medium- or High-Risk Applications
The best way to understand the capabilities of mobile health ap-
plications—and the health concerns that may require FDA
regulation—is through examples. Some health applications, such as
electronic health records or fitness apps, pose a low-health risk.49
Other apps, such as those that directly involve diagnosis and treat-
ment of patients, can pose a much higher health risk.50 This already
blurry conceptual line will likely become even more obscure as
technology advances. Moreover, this definitional difficulty creates a
regulatory paradox for the FDA.
www.slu.edu/Documents/law/SLUJHP/Archives/Vol7-2/Carroll_Article.pdf (“Many ill-
nesses can manifest the same set of symptoms, but a complete diagnosis requires more than
simply checking off boxes in a list; it requires learned intuition.”).




45. MOBI HEALTH NEWS, WIRELESS HEALTH: STATE OF THE INDUSTRY 2009 YEAR END RE-
PORT 1, 5 (2009), available at http://mobihealthnews.com/wp-content/Reports/2009Stateof
theIndustry.pdf.
46. Id. at 2.
47. Id. at 2–3.
48. Kevin Pho, Health App Users Beware, USA TODAY (Apr. 2, 2014), http://www.usatoday
.com/story/opinion/2014/04/02/medical-app-fitness-health-fda-technology-column/7224
837/.
49. See Diana, supra note 18.
50. See Pho, supra note 48.
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Low-risk applications generally “store, organize, or track health
information, or provide general disease management or health rec-
ommendations.”51 Such apps allow the user (generally the patient)
to read about a medical condition or treatment, input his or her
own data, and gather resources to make more informed decisions.52
Some examples of these applications include:
• Epocrates—which allows the user to review drug prescrip-
tion and safety information, check potentially harmful drug-
to-drug interactions, and identify a pill by its physical charac-
teristics (e.g. color, size, etc.) and imprinted symbol.53
Epocrates has more than one million active users, including
fifty percent of physicians in the United States.54
• LactMed—which aggregates all drugs and dietary supple-
ments that may affect breastfeeding, includes information
on the levels of such substances in breast milk and infant
blood, and lists possible adverse effects in the nursing in-
fant.55 LactMed was developed by the National Library of
Medicine’s Toxicology Data Network.
• Microdex Drug Reference—which purports to contain the
“most trusted drug information” of any health and wellness
application, including generic names, therapeutic class,
black box warnings, dosages, adverse effects, and more.56
• MyFitnessPal—which maintains a database of over five mil-
lion foods and allows users to track their daily calorie
intake.57
Because of the limited capabilities of these apps, there is little
risk that a user will be misinformed in a harmful way.
51. Sidley Updates, Sidley Austin, FDA Says it Will Not Actively Regulate Low-Risk Mo-
bile Medical Apps (Oct. 1, 2013), http://www.sidley.com/FDA-Says-it-will-not-Actively-
Regulate-Low-Risk-Mobile-Medical-Apps-10-01-2013/.
52. See id.
53. Mobile Products, EPOCRATES INC., http://www.epocrates.com/mobile (follow “Fea-
tures” hyperlink; then follow “Pill ID” hyperlink) (last visited Mar. 20, 2015).
54. Epocrates, ANDROID APPS ON GOOGLE PLAY, https://play.google.com/store/apps/de-
tails?id=com.epocrates&hl=en (last visited Mar. 20, 2015).
55. LactMed, ITUNES, https://itunes.apple.com/us/app/lactmed/id441969514?mt=8
(last visited Mar. 20, 2015).
56. Free Micromedex Drug Reference, ANDROID APPS ON GOOGLE PLAY, https://play.google
.com/store/apps/details?id=com.truven.druginfonative.customer  (last visited Mar. 20,
2015).
57. Calorie Counter & Diet Tracker by MyFitnessPal, ITUNES, https://itunes.apple.com/us/
app/calorie-counter-diet-tracker/id341232718?mt=8 (last visited Mar. 20, 2015).
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In contrast to these low-risk apps, those that aim to replace the
decision-making processes normally performed by medical profes-
sionals have the potential to present greater health risks, and
transform an innocuous mobile device into a medical device that
the FDA should monitor.58 Some examples of these applications
include:
• Instant Heart Rate—which takes the user’s heart rate by al-
lowing the user to place her finger over the camera for
several seconds.59 The application acts as a medical “pulse
oximeter” by tracking color changes in the light that passes
through the user’s finger.60
• EyeNetra—which purports to perform an eye exam from
the user’s phone.61 The application, developed by research-
ers at the Massachusetts Institute of Technology, requires an
add-on piece62 through which the user is instructed to look;
EyeNetra will then indicate if the user is nearsighted, far-
sighted, or has astigmatism.
• Isabel App—which allows the user to enter symptoms and
search a database of over 6,000 diseases.63 While “not de-
signed to provide a diagnosis . . . [Isabel will] provide you
with a list of likely diagnoses to consider when you have
doubt.”64
• iStethoscope—which allows users to record their heartbeats
and see their heart waveforms by “turn[ing] your iPhone
into a stethoscope.”65 iStethoscope can also display a phono-
cardiograph or send the recording and images to anyone,
like a doctor, through email.
Although it may appear easy to separate these classes of applica-
tions, the dividing line between low- and medium- or high-risk
applications becomes more complicated by how patients actually
58. See Sidley Update, FDA Says it Will Not Actively Regulate, supra note 51.
59. Instant Heart Rate, ITUNES, https://itunes.apple.com/us/app/instant-heart-rate-
heart-rate/id395042892?mt=8 (last visited Mar. 20, 2015).
60. Id.
61. Eye Exam? There’s An App For That: Think of Device As ‘Thermometer for the Eye, ABC 7
NEWS DENVER (Oct. 4, 2010), http://www.thedenverchannel.com/lifestyle/health/eye-exam-
there-s-an-app-for-that.
62. The add-on piece costs two dollars. Id.
63. Isabel, ITUNES, https://itunes.apple.com/us/app/isabel/id473503904?mt=8 (last vis-
ited Mar. 20, 2015).
64. Id.
65. iStethoscope Pro, ITUNES, https://itunes.apple.com/us/app/istethoscope-pro/id32211
0006?mt=8 (last visited Mar. 20, 2015).
SUMMER 2015] Can You Diagnose Me Now? 1083
use the applications. Some facially low-risk applications provide
users with information that informs their subsequent self-treatment,
transforming seemingly innocuous applications into medium- or
high-risk applications. For example, Cures A-Z is an application that
purports to be a “free Comprehensive Medicine specialist in your
pocket!”66 The application contains a complete list of health condi-
tions and their treatments in order for users to self-manage an
illness. While at first glance this application appears to be a low-risk
application, this categorization could shift if patients self-diagnose
and self-manage their illnesses based on information collected from
the application. As one user commented, “this app has provided . . .
ways that I can help myself instead of running to the doc . . .”67
Thus, patients can use this information not simply for their own
knowledge, but to actually diagnose and treat their ailments.68 Ac-
cordingly, a successful regulatory scheme should not rely on strictly
risk-based categories; instead, it should account for the fact that pa-
tients may use applications in ways developers did not anticipate.
II. THE FDCA: FDA’S STATUTORY AUTHORITY OVER MOBILE
MEDICAL APPLICATIONS
The term “FDA regulated medical device” evokes images of med-
ical hardware, X-ray machines, pacemakers, thermometers, and
stethoscopes,69 rather than a mobile phone application that reads
your heart rate.70 The FDCA, nevertheless, grants the FDA the statu-
tory authority to regulate all of these products—both hardware and
software intended for use in diagnosing, curing, mitigating, treat-
ing, or preventing a disease or other condition71—as “medical
devices.”72 The FDA, thus, clearly has regulatory authority over the
software used to develop mobile medical applications.73
66. Cures A-Z, ITUNES, http://itunes.apple.com/us/app/cures-a-z/id297648638?mt=8
(last visited Mar. 20, 2015).
67. HayLady1, Comment to Cures A-Z, ITUNES, http://itunes.apple.com/us/app/cures-
a-z/id297648638?mt=8 (last visited Mar. 20, 2015).
68. See Krouse, supra note 26, at 743.
69. See generally Is The Product a Medical Device?, U.S. FOOD & DRUG ADMIN., http://www
.fda.gov/medicaldevices/deviceregulationandguidance/overview/classifyyourdevice/ucm05
1512.htm [hereinafter Medical Devices].
70. See Instant Heart Rate, supra note 59.
71. See 21 U.S.C. § 321(h)(2) (2006).
72. See id. § 321(h).
73. See Richard A. Merrill, The Architecture of Government Regulation of Medical Products, 82
VA. L. REV. 1753, 1754 (1996) (explaining that it is “virtually impossible to market a new
medical product without FDA’s review and concurrence”); JUDITH A. JOHNSON, CONG. RE-
SEARCH SERV., R42130, FDA REGULATION OF MEDICAL DEVICES 1 (2012), available at http://
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The FDA’s authority to regulate medical devices and software has
evolved incrementally. In 1906, Congress created the FDA when it
enacted the first major federal law governing therapeutic drugs.74
At this point, beyond dental tools, the medical device industry in-
cluded few products intended for prolonged application to, much
less installation in, the human body.75 Further, physician tools, lim-
ited to instruments like stethoscopes, did not pose risks beyond
those associated with careless or untrained use.76 As a result, medi-
cal devices were not thought to be “appropriate candidates for
federal regulation.”77
During the Great Depression, social advocacy groups pioneered
policies designed to protect consumers.78 These efforts included
the 1938 Food, Drug, and Cosmetic Act (the 1938 Act), which, for
the first time, expanded FDA’s authority to include the regulation
of medical devices.79 This expanded authority resulted in mixed
success. In some instances, the FDA successfully contested the un-
proven therapeutic claims made by the creators and marketers of
several “quack” devices, like the “Halox Therapeutic Generator”
and the “Electreat Mechanical Heart.”80 However, the FDA still
“had no authority to require the manufacturer of any device to
prove the safety, much less the effectiveness, of its product.”81 This
lack of regulatory authority stymied many of the FDA’s efforts to
www.fas.org/sgp/crs/misc/R42130.pdf (“Medical devices regulation is complex, in part, be-
cause of the wide variety of items that are categorized as medical devices.”).
74. See JAMES HARVEY YOUNG, THE MEDICAL MESSIAHS: A SOCIAL HISTORY OF HEALTH
QUACKERY IN TWENTIETH-CENTURY AMERICA 54, 242 (1967) (noting that the definition of drug
in 1906 law left a large loophole for devices and that as a result, though “[d]evice quackery
was ancient in America, . . . not until the 1938 law did the FDA secure authority to act against
it.”); Rodney R. Munsey, Trends and Events in FDA Regulation of Medical Devices Over the Last
Fifty Years, 50 FOOD & DRUG L.J. 163, 163 (1995) (noting the link between the rise in “quack
medical devices” and congressional consideration of increasing the FDA’s regulatory
authority).
75. See S. REP. NO. 94–33, at 2–3 (1975) (cataloging some such items).
76. See Merrill, supra note 73, at 1801.
77. See id.
78. See The 1938 Food, Drug, and Cosmetic Act, U.S. FOOD & DRUG ADMIN., http://www.fda
.gov/AboutFDA/WhatWeDo/History/ProductRegulation/ucm132818.htm (last visited May
10, 2015) [hereinafter The 1938 FDCA].
79. Id.
80. See United States v. 22 Devices, More or Less, Halox Therapeutic Generator, 98 F.
Supp. 914, 917–18 (S.D. Cal. 1951) (condemning devices as misbranded); United States v. 6
Devices, “Electreat Mech. Heart,” 38 F. Supp. 236, 238 (W.D. Mo. 1941) (condemning the
“Mechanical Heart” as misbranded); see also United States v. One Device, Intended for Use as
a Colonic Irrigator, 160 F.2d 194, 200 (10th Cir. 1947) (sustaining action against “Tox-
Eliminator”).
81. Merrill, supra note 73, at 1802–03; see also H.R. REP. NO. 94–853, at 6 (1976); David
F. Cavers, The Food, Drug, and Cosmetic Act of 1938: Its Legislative History and its Substantive
Provisions, 6 LAW & CONTEMPORARY PROBLEMS 2, 23 (1939), available at http://scholar-
ship.law.duke.edu/lcp/vol6/iss1/2 (“It suffices here to say that the principal act prohibited
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remove products with no value in the prevention or treatment of
disease.82
The FDA began to push for stronger regulatory authority over
medical devices in the 1960s with the introduction of highly sophis-
ticated medical technologies.83 The FDA perceived the need for
regulatory authority over leg braces and wheel chairs quite differ-
ently from artificial joints and heart pacemakers, which presented
very different regulatory considerations.84 In 1962, the FDA unsuc-
cessfully lobbied Congress for an amendment to the FDCA that
would have required pre-market proof of safety and effectiveness
for medical devices. As a result of that failure, the Agency was left
with only the 1938 Act’s minimal enforcement tools.85 Despite the
failure of that amendment, a consensus grew among healthcare
professionals, manufacturers, and FDA officials that the 1938 Act
provided an inadequate framework to regulate medical devices.86
After nearly a decade of debate on the proper regulatory sys-
tem,87 in 1976, Congress amended the FDCA with the Medical
Device Amendments (MDA).88 The lengthy amendments89 broadly
defined a medical device as:
“an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article,
by the statute is the introduction into interstate commerce ‘of any food, drug, device, or
cosmetic that is adulterated or misbranded.’ ”).
82. See Merrill, supra note 73, at 1803.
83. See id.
84. See id.
85. See Peter Barton Hutt, A History of Government Regulation of Adulteration and Misbrand-
ing of Medical Devices, 44 FOOD DRUG COSM. L.J. 99, 106 (1989); Peter Barton Hutt, Richard A.
Merrill & Alan M. Kirschenbaum, The Standard of Evidence Required for Premarket Approval Under
the Medical Device Amendments of 1976, 47 FOOD & DRUG L.J. 605, 609–10 (1992).
86. The FDA successfully used the 1938 Act’s expansive definition of “drug” to claim
that certain diagnostic medical devices qualified as “new drugs” and required pre-market
approval. For example, in United States v. An Article of Drug . . . Bacto-Unidisk . . . the Supreme
Court upheld the FDA’s determination that an antibiotic sensitivity disk, a product that never
came into contact with the patient’s body, was a “drug” subject to FDA regulation. 394 U.S.
784, 800 (1969); see Merrill, supra note 73, at 1805–06.
87. See, e.g., DEP’T OF HEALTH, EDUC. AND WELFARE, STUDY GROUP ON MEDICAL DEVICES,
MEDICAL DEVICES: A LEGISLATIVE PLAN (1970) (describing a model for medical device legisla-
tion); Theodore Cooper, Device Legislation, 26 FOOD DRUG COSM. L.J. 165 (1971) (same).
88. Pub. L. No. 94-295, 90 Stat. 39 (1976) (codified in scattered sections of 21 U.S.C.);
see also Gail H. Javitt, I’ve Got You Under My Skin—and I Can’t Get Redress: An Analysis of Recent
Case Law Addressing Preemption of Manufacturer Liability for Class III Medical Devices, 49 FOOD &
DRUG L.J. 553, 558–59 (1994); Lars Noah, Amplification of Federal Preemption in Medical Device
Cases, 49 FOOD & DRUG L.J. 183, 184 (1994).
89. The 1976 Amendments cover forty-five pages in the Statutes at Large. 90 Stat. 539-83
(1976). By comparison, the entire 1938 Act took up just twenty pages. See 52 Stat. 1040-59
(1938).
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including any component, part, or accessory, which is . . . in-
tended for use in the diagnosis of disease or other conditions, or
in the cure, mitigation, treatment, or prevention of disease . . .
or intended to affect the structure or function of the body.”90
Analysis of this statutory definition often centers on the broad
determination of an article’s “intended use.” To determine the in-
tended use, the FDA looks at a product’s “labeling claims,
advertising matter, or oral or written statements by [manufacturers]
or their representatives.”91 Generally, an article—including
software—is considered a medical device if it is intended for a med-
ical purpose.92 The MDA, therefore, granted the FDA expansive
regulatory power: the “intended use” modifier statutorily authorizes
the FDA to regulate certain products based solely on their manufac-
turer’s advertising statements.93
The FDA regulates medical devices based on a three-tiered risk
analysis.94 Under this classification system, the Agency determines
the amount of pre-market and post-market regulation required by
the FDCA. The three levels of control are:
• Class I devices necessitate the least regulatory control.95 Pro-
ducers of Class I devices can generally market those goods
without any pre-market review.96 Examples of Class I devices
include tongue depressors, elastic bandages, and examina-
tion gloves.97
90. 21 U.S.C. § 321(h) (2012) (emphasis added).
91. 21 C.F.R. § 801.4 (2015).
92. See Scott D. Danzis & Christopher Pruitt, Rethinking the FDA’s Regulation of Mobile




93. The regulatory language for medical devices and drugs is identical. However, the
level of regulation is much less strict for most devices. Cf. id. (explaining that articles in-
tended as health and wellness devices—like treadmills—are not regulated as medical
devices).
94. See Regulatory Controls, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Medi-
calDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/default
.htm (the FDA did not complete the classification process until 1988); see also PETER BARTON
HUTT & RICHARD A. MERRILL, FOOD AND DRUG LAW: CASES AND MATERIALS 751 (2d ed. 1992).
95. Class I medical devices are only subject to “general controls” that include registra-
tion of the company and device, and tracking the company’s activities. See Regulatory Controls,
supra note 94.
96. See id.
97. See Classification of Medical Devices, LITRON INC., http://www.litron.com/Classifica-
tion-of-Medical-Devices.asp (last visited Mar. 20, 2015).
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• Class II devices represent an intermediate level of risk, and
the FDA requires manufacturers to submit device-specific
“special controls.”98 The FDA classified over half of the pre-
1976 devices as Class II, including X-ray machines, powered
wheelchairs, and acupuncture needles.99
• Class III devices entail the greatest risk and generally re-
quire pre-market approval,100 a complex and expensive
process that obligates the manufacturer to submit clinical
data proving the device’s safety and effectiveness.101 This ap-
proval process resembles the procedures for new
therapeutic drugs, which demonstrates the FDA’s view that
medical devices can pose similar dangers to health.102 Exam-
ples of Class III devices include implantable pacemaker
pulse generators and endosseous implants.103
This three-tiered regulatory approach demonstrates a recogni-
tion of the need for a flexible, dynamic approach to medical device
regulation.104 The regulatory scheme “calibrate[s] regulatory re-
quirements to the risks and uncertainties presented by specific
devices.”105 To this end, the MDA also gives the FDA the authority
to set good manufacturing practice requirements for medical de-
vices,106 to ban worthless and dangerous products from the
market,107 and to require notification, replacement, or refund by
makers of defective products.108
Although software is not expressly discussed in the FDCA, the
FDA “has long considered software products to meet the definition
of a device when [the software is] intended for use in diagnosing
98. Class II medical devices are subject to “general controls” and “special controls” that
include: performance standards, post-market surveillance, patient registries, special labeling
requirements, pre-market data requirements, and guidelines. See Regulatory Controls, supra
note 94.
99. See Merrill, supra note 73, at 1815; Classification of Medical Devices, supra note 97.
100. See Medical Devices, supra note 69.
101. In 2012, the fees for pre-market notification were $4,717, whereas the costs for sub-
mitting a device for pre-market approval “can reach $1,000,000, plus user fees of an
additional . . . $256,384. . . .” 21 C.F.R. § 880, available at http://www.gpo.gov/fdsys/pkg/FR-
2008-02-08/html/E8-2325.htm.
102. See Merrill, supra note 73, at 1809.
103. See Medical Devices, supra note 69.
104. See Merrill, supra note 73, at 1806; see also DEP’T OF HEALTH, EDUC. AND WELFARE,
STUDY GROUP ON MEDICAL DEVICES, MEDICAL DEVICES: A LEGISLATIVE PLAN (1970); Cooper,
supra note 87.
105. See Merrill, supra note 73, at 1809.
106. Medical Device Amendments of 1976, Pub. L. No. 94-295, § 520(f)(1)(A), 90 Stat.
539, 567 (1976) (codified as amended at 21 U.S.C. § 360j(f)(1)(A) (1994)).
107. Id. § 516.
108. Id. § 518.
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and treating diseases and other conditions.”109 In 1989, the FDA
first addressed its statutory authority over software.110 In its Draft
Guidance for the Regulation of Computer Products, the Agency as-
serted: “To the extent that computer products used in medicine are
intended to affect the diagnosis and treatment of patients and thus
are medical devices, the [FDA] must provide reasonable assurance
that these products are safe and effective.”111 While the FDA affirm-
atively declared its general statutory authority over software, the
Agency announced that it would exercise enforcement discretion
over many types of low-risk software, such as software that merely
provided “traditional library . . . functions.”112 According to one
commentator, Dale Cooke, Vice President and Group Director of
Digitas Health, “When FDA asserts that it will exercise regulatory
discretion [over software], it is stating that (it) has the legal author-
ity to enforce regulations, but that it is choosing not to do so.”113
Thus, even if the FDA chooses not to actively regulate certain
software, this does not detract from its broad authority to regulate
software as medical devices.114
The FDA’s historical approach to regulating stand-alone software
emphasizes the Agency’s view that a more nuanced, lighter regula-
tory touch is appropriate. The 1989 Draft Guidance set a reserved
regulatory approach to software; those standards stated that the
FDA likely would not apply the FDCA to computer products “that
are intended to involve competent human intervention before any
impact on human health occurs.”115 Under this policy, the FDA ex-
ercises its discretion to withhold enforcement of the FDCA on such
software as:
109. Danzis & Pruitt, supra note 92, at 2.
110. U.S. FOOD & DRUG ADMIN., FDA POLICY FOR THE REGULATION OF COMPUTER PROD-




113. FDA Mobile App Guidance Focuses on Risk, Calls for “Enforcement Discretion,” COAL. FOR
HEALTHCARE COMMC’N (Sept. 30, 2013), http://www.cohealthcom.org/2013/09/30/fda-mo-
bile-app-guidance-focuses-on-risk-calls-for-%E2%80%9Cenforcement-discretion%E2%80%
9D/.
114. Certain software systems are statutorily exempted from the FDA’s device authority.
See 21 C.F.R. § 807.65(c) (1993) (exempting general purpose software, like spreadsheet and
word processing software); 21 C.F.R. § 807.65(d) (exempting software manufactured by med-
ical practitioners solely for their own practices); 21 C.F.R. § 807.65(f) (exempting software
intended solely for use in nonclinical research, teaching, and analysis).
115. U.S. FOOD & DRUG ADMIN., supra note 110.
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• software intended only for use to perform traditional “li-
brary” functions, such as storage, retrieval, and
dissemination of medical information;
• software intended only for use in general accounting or
communication functions; and
• software intended for educational purposes rather than for
diagnosis or treatment.116
Conversely, the FDA applied the FDCA to software like labora-
tory information systems (LIS), as well as picture archiving and
communications systems (PACS).117
The FDA never codified or formalized the 1989 Draft Gui-
dance.118 In fact, in 2005 the Agency withdrew the 1989 Draft
Guidance, and reiterated its longstanding policy that because of the
“history, complexity, and diversity of computer systems and control-
ling software, it would be impractical to adopt one ‘software’ or
‘computer’ policy to address all computer and software medical de-
vices.”119 The Agency continues to apply its general three-tiered risk
analysis to these devices, which classifies different software systems
as Class I and II medical devices, yet never as Class III devices.120 In
summary, the regulatory question is not if the FDA has the statutory
authority to regulate software, but rather how it can best utilize this
authority to advance public health in relation to the rapidly evolv-
ing software of mobile health applications.
III. FDA REGULATION OF MOBILE APPLICATIONS
Since the first mobile health application reached the market in
1997, the FDA has regulated mobile applications as medical de-
vices.121 Since 2008, when mobile applications became more
116. Id.; see also 70 Fed. Reg. 824, 890 (Jan. 5, 2005); 76 Fed. Reg. 8637, 8638 (Feb. 15,
2011); U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL., MOBILE MEDICAL APPLICATIONS: DRAFT
GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF (2015), available at www
.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/
UCM263366.pdf.
117. Danzis & Pruitt, supra note 92, at 2.
118. Medical Devices, supra note 69; Medical Device Data Systems, 76 Fed. Reg. 8637, 8638
(Feb. 15, 2011) (codified at 21 C.F.R. pt. 880).
119. Id.
120. See, e.g., 21 C.F.R. § 862.2100 (2015) (classifying laboratory information systems as
Class I device); 21 C.F.R. § 892.2010–20 (2015) (classifying medical imaging management
systems as Class I and II devices); 76 Fed. Reg. 8637, 8641 (classifying medical device data
systems as Class I device).
121. See Health Information Technologies: Administration Perspectives on Innovation and Regula-
tion Before the H. Energy & Commerce Comm., 113th Cong. (testimony of Christy Foreman,
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pervasive and complex, the FDA started to develop a more defined
regulatory scheme for this technology. In September 2013, the FDA
announced a revised scheme in its 2013 Final Guidance.122 This
Part explores the FDA’s historical approach to mobile applications
and the Final Guidance, and identifies unanswered regulatory
questions.
A. Early Enforcement of the FDCA for Mobile Applications
Early on, developers were uncertain about how the FDA would
exercise its statutory authority to regulate mobile applications.123
The story of MIM Software clearly reflects this uncertainty.  In 2008,
immediately after the App Store launched, MIM Software created
and uploaded the first medical application to the App Store:
MobileMIM.124 MobileMIM allowed physicians to view CT, MRI,
and PET scan images on an iPhone and thus to immediately “make
diagnoses without having to be back at the workstation or wait for
film.”125 Shortly thereafter, MIM Software pulled MobileMIM from
the App Store due to regulatory concerns.126 According to Mark
Cain, the Chief Technology Officer of MIM Software, the FDA’s
regulatory authority forced MIM Software to cease distribution of
MobileMIM: “We put [the app] out on the [App Store] for free on
Day [One]. We knew that the FDA governs commercial distribution
of devices so we thought a free app would not need approval. But
when they found the app in the App Store, they ordered us to take
it down.”127 Subsequently, in July 2008, MIM Software submitted
Director, Office of Device Evaluation, Center for Devices and Radiological Health), available
at http://energycommerce.house.gov/hearing/health-information-technologies-administra-
tion-perspectives-innovation-and-regulation.
122. Press Release, U.S. Food & Drug Admin., FDA Issues Final Guidance on Mobile
Medical Apps (Sept. 23, 2013), available at http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm369431.htm.
123. Ken Block, FDA Goes Mobile: Regulation of Medical Apps, EUR. MED. DEVICE TECH. (Apr.
21, 2014), http://www.emdt.co.uk/daily-buzz/fda-goes-mobile-regulation-medical-apps.
124. Chris Gullo, Mobile MIM Receives Second FDA Clearance, MOBI HEALTH NEWS (Dec. 19,
2011), http://mobihealthnews.com/15363/mobile-mim-receives-second-fda-clearance/.
125. Press Release, U.S. Food & Drug Admin., FDA Clears First Diagnostic Radiology Ap-
plication for Mobile Devices (Feb. 4, 2011), available at http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm242295.htm.
126. Chris Seper, iPad Radiology App Wins FDA Approval in Breakthrough for Mobile Imaging,
MEDCITY (Feb. 4, 2011), http://medcitynews.com/2011/02/iphone-ipad-radiology-app-wins-
fda-approval/.
127. Felasfa Wodajo, How the iPad Radiology App MobileMIM Became the First to Get FDA
Approval: Interview with CTO Mark Cain, IMEDICALAPPS (Apr. 14, 2011), http://www.imedi-
calapps.com/2011/04/how-the-ipad-radiology-app-mobilemim-became-the-first-to-get-fda-
approval-interview-with-cto-mark-cain/.
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MobileMIM to the FDA for approval. According to Cain, “Within
[one] week, there were a lot of questions and a lot of confusion.
The FDA was confounded that [MIM developers] were not making
hardware. The fact that it was a phone was confusing.”128 Ulti-
mately, in February 2011, after two years of dialogue between MIM
Software and the FDA, the FDA approved MobileMIM.129
B. The FDA’s Mobile Medical Application Guidance Documents
To clarify regulatory uncertainty, the FDA issues guidance docu-
ments to alert the medical field to the “FDA’s current [regulatory]
thinking” as to how it intends to enforce its broad statutory author-
ity.130 The guidance documents “do not create or confer any rights
for or on any person and do not operate to bind FDA or the pub-
lic.”131 Rather, they signal the FDA’s current policy towards
exercising enforcement discretion for various subsets of medical de-
vices.132 Thus, guidance documents do not alter the FDA’s
authority, which extends to the limits defined by the FDCA, and the
FDA can at any point change its view on how to enforce the Act.133
For mobile applications, the FDA issued its regulatory guidance in
draft and final form: the 2011 Draft Guidance and the 2013 Final
Guidance.
1. 2011 FDA Draft Guidance
In July 2011, the FDA released its Draft Guidance, setting forth a
proposal to regulate mobile applications.134 The FDA planned to
regulate a subset of mobile applications that both (1) met the
broad definition of a medical device and (2) served as an accessory
to a “regulated medical device” or transformed a mobile platform
into a “regulated medical device.”135 The second requirement
128. Id.
129. See The 1938 FDCA, supra note 78.
130. Regulatory Information: Search for FDA Guidance Documents, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/RegulatoryInformation/Guidances/ (last visited May 10, 2015).
131. Id.
132. See id.
133. See Anthony Vale, Can a State Impose Civil Penalties on a Drug or Device Company for
Using a Federally-Approved Label?, 11 BLOOMBERG PHARMACEUTICAL L. & INDUSTRY REP. NO. 40
(Oct. 30, 2013), available at http://www.pepperlaw.com/publications_article.aspx?ArticleKey
=2780 (“Congress gave the FDA exclusive authority to enforce the FDCA.”).
134. See U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL., supra note 116.
135. See id.
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would include apps that (a) act as an accessory to a regulated medi-
cal device (e.g., remotely displaying data from a bedside monitor);
(b) transform a mobile platform into a traditionally regulated medi-
cal device (e.g., an iPhone app that can perform the functions of a
stethoscope); or (c) generate a patient-specific result, through for-
mulae or processing algorithms that respond to user entered,
patient-specific information.136 The FDA termed qualifying applica-
tions “mobile medical applications.”
The Agency received 130 responses when it released the Draft
Guidance for public comment.137 Although some commenters
praised the FDA’s willingness to exercise discretion to refrain from
enforcement against some applications, industry stakeholders criti-
cized the Draft Guidance for its lack of clarity.138 The Draft
Guidance appeared to maintain the FDA’s active regulation of
some apps that perform very basic clinical analysis, including
merely automating simple and well-understood clinical calculations
and algorithms. For example, an Apgar scoring application—used
to quickly and summarily assess the health of a newborn child im-
mediately after birth—would simply add together five variables that
could range from 0–2, yet qualified for regulation under the Draft
Guidance.139 One critic claimed that “requiring an app of this sort
to comply with the host of regulatory requirements applicable to
medical devices [is] excessive.”140 Likewise, part of the Draft Gui-
dance tangled its own nomenclature. In one section, the Draft
Guidance discussed mobile apps subject to enforcement discre-
tion—or apps the FDA will not actively regulate—but then
described those apps as “mobile medical apps,” which is the title the
FDA gives to mobile apps it would actively regulate.141
Although the Draft Guidance recognized the unique characteris-
tics of mobile applications142 and treaded lightly when enforcing
the FDCA with respect to mobile medical apps, the Agency still re-
tained oversight of health-related software. Rather than send a
136. See id.
137. Examining Federal Regulation of Mobile Medical Apps and Other Health Software: Hearing
Before the  Subcomm. on Health, Comm. on Energy & Commerce, 113th Cong. (2013) (statement
of Jeffrey Shuren, Director, Center for Devices and Radiological Health) available at http://
www.fda.gov/NewsEvents/Testimony/ucm375462.htm.




142. See, e.g., Mobile Medical Applications, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
MedicalDevices/ProductsandMedicalProcedures/ConnectedHealth/MobileMedicalApplica-
tions/ucm255978.htm (last updated June 4, 2014) (recognizing the unique characteristics of
different mobile platforms).
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warning letter—the traditional FDA method of notifying a com-
pany that the Agency “considers one or more products . . . to be in
violation of the [FDCA]”143—the FDA proposed “exercis[ing] nota-
ble restraint by sending an ‘It Has Come to Our Attention
Letter.’ ”144 For example, in May 2013, the FDA informed Biosense
Technologies that its urinalysis app, uChek, qualified as a medical
device because it performed the same task as a traditional medical
device—urinalysis test system—albeit without the urinalysis dip-
stick.145 The app reads the user’s dipstick and tracks several
parameters, such as glucose, pH, and protein levels, as seen in the
user’s urine.146 The FDA’s letter advised Biosense that “any com-
pany intending to promote their device for use in analyzing,
reading, and/or interpreting these dipsticks needs to obtain clear-
ance for the entire urinalysis test system (i.e., the strip reader and
the test strips, as used together).”147 However, the letter also indi-
cated that the agency planned to approach enforcement in the area
of medical applications in a measured fashion, taking a case-by-case
approach.148 The FDA thus fulfilled its stated mission of notifying
companies of potential regulatory obligations while withholding de-
finitive decisions.
Overall, the Draft Guidance received praise for opening a dia-
logue between regulators and industry to try to help the FDA better
understand the ever-developing mobile applications market.
2. 2013 FDA Final Guidance
After two years of review, which included consideration of scores
of comments from medical experts,149 on September 25, 2013, the
143. See U.S. FOOD & DRUG ADMIN., REGULATORY PROCEDURES MANUAL: EXHIBIT 4-1 PROCE-
DURES FOR CLEARING FDA WARNING LETTERS AND UNTITLED LETTERS (2012), available at http:/
/www.fda.gov/downloads/ICECI/ComplianceManuals/RegulatoryProcedures Manual/
UCM176965.pdf.
144. Suzan Onel, Where the “App” World and FDA Collide: Current Status of the FDA’s Regula-
tion of Medical Device Software and Mobile Medical Apps, in RECENT DEVELOPMENTS IN FOOD AND
DRUG LAW 153–74 (2014 ed. 2013).
145. See Letter from FDA, to Biosense Technologies Private Limited, Concerning the
uChek Urine Analyzer (May 21, 2013), available at www.fda.gov/MedicalDevices/Resources-
forYou/Industry/ucm353513.htm.
146. Pooja Jaeel, Smartphone App Enables Mobile Analysis of Urine for Disease Pathology, IMEDI-
CALAPPS (May 1, 2013), http://www.imedicalapps.com/2013/05/smartphone-app-enables-
mobile-analysis-urine-disease-pathology/.
147. See Letter from FDA to Biosense Technologies, supra note 145.
148. See id.
149. See Press Release, FDA Issues Final Guidance on Mobile Medical Apps, supra note
122.
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FDA released its Final Guidance for mobile medical applications.150
The FDA preserved the Draft Guidance’s basic approach of limiting
active regulation to “mobile medical applications,” those mobile
apps that can be used “as an accessory to a medical device already
regulated by the FDA”151 or that “transform a mobile device into a
medical device already regulated by the FDA.”152 The Final Gui-
dance specified that the FDA would tailor regulatory mechanisms
in accordance with the same categories used for other medical de-
vices, namely as class I (general controls), class II (special controls
in addition to general controls), or class III (pre-market
approval).153
To better define mobile medical applications, the Final Gui-
dance included detailed appendices of three different categories of
applications.154 The Final Guidance included these reference
guides to help companies determine whether their application is
subject to active FDA regulation. The first category includes those
applications that the FDA does not classify as medical devices.155 As
such, the FDA will not regulate these applications. These applica-
tions include those meant to serve as medical references for both
physicians and patients (such as electronic medical dictionaries or
textbooks), educational apps used by healthcare providers for med-
ical training, or apps meant to facilitate medical office functions,
such as scheduling doctor shifts or tracking insurance claim data.156
The second category includes those applications that meet the
definition of a medical device, but for which the FDA intends to
refrain from regulating because the application poses a low risk to
patient safety.157 For example, applications that provide supplemen-
tal clinical care through coaching or prompting to help patients
manage their health—such as a reminder to the patient to exer-
cise158—will not face active FDA regulation.
The last category includes those applications that the FDA con-
siders medical devices and that the FDA believes pose a significant
risk of patient harm if they were to function improperly.159 These
150. See FINAL GUIDANCE, supra note 11.
151. Id.
152. Id.
153. Id. at 13.
154. Id. at 20–22.
155. Id.
156. Id.; see also David L. Rosen, FDA Submits Final Guidance on Mobile Medical Apps, FOLEY
& LARDNER LLP (Oct. 4, 2013), http://www.foley.com/fda-submits-final-guidance-on-mobile-
medical-apps-10-04-2013/.
157. FINAL GUIDANCE, supra note 11, at 18.
158. See Rosen, supra note 156.
159. FINAL GUIDANCE, supra note 11, at 15–16.
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types of apps can either enable a mobile device to operate as a regu-
lated medical device—e.g., use of sensors to measure certain bodily
fluids160—or enable a device to operate as a controller for a regu-
lated medical device—e.g., a wireless remote for an X-ray
machine.161 The FDA intends that apps in this category will be sub-
ject to the same risk-based approach used by the agency to assess
and regulate traditional medical devices.
As with traditional medical devices, the FDA’s approach to mo-
bile applications is “focused on their functionality” or “intended
use.”162 In general, if a mobile app is intended to perform a medical
device function,163 it is a medical device, regardless of the platform
on which it is run.164 For example, several mobile applications run
on smartphones to analyze and interpret EKG waveforms to detect
heart function irregularities.165 The FDA will treat these applica-
tions like analogous software running on a desktop computer,
which falls under purview of 21 CFR § 870.2340 (“Electrocardio-
graph”). The FDA intends to apply its regulatory oversight to only
those mobile apps that, “are medical devices and whose functional-
ity could pose a risk to a patient’s safety if the mobile app were to
not function as intended.”166
Ultimately, the Final Guidance is a progressive regulatory scheme
because of its reserved approach. That is, the FDA chose to exercise
enforcement discretion—or non-enforcement—with respect to the
vast majority of mobile applications, “focus[ing] its regulatory over-
sight on a subset of mobile medical [applications] that present a
greater risk to patients if they do not work as intended.”167 Demon-
strating this, between the February 2011 Draft Guidance and
September 2013 Final Guidance,168 FDA approved approximately
160. See Rosen, supra note 156.
161. Id.
162. FINAL GUIDANCE, supra note 11, at 8.
163. A mobile app performs a medical device function if it operates “for diagnosis of
disease or other conditions, or the cure, mitigation, treatment, or prevention of disease.” Id.
164. The FDA’s oversight is not determined by the platform. See id. (“Under this gui-
dance, FDA would not regulate the sale or general/conventional consumer use of
smartphones or tablets.”).
165. Id.
166. Id. at 13.
167. See Press Release, FDA Issues Final Guidance on Mobile Medical Apps, supra note
122.
168. To reiterate, the law—the FDCA—never changed in this time period (or before, for
that matter). Therefore, the deft touch with which the FDA enforced the FDCA with mobile
health applications during this period is a strong predictor for FDA enforcement going
forward.
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40 mobile medical applications.169 This number, compared to the
over 40,000 mobile health applications made available to consum-
ers,170 shows FDA’s hesitancy to strongly regulate mobile
applications.
3. Ambiguity in the Risk-Based Regulatory Scheme
Although the 2013 Final Guidance has been lauded by many in-
dustry experts for its prudent regulatory approach,171 its risk-based
regulatory scheme does not clearly define the apps that the FDA
will actively regulate. The Final Guidance states that the FDA will
actively regulate any app that “could pose a risk to a patient’s safety”
if the app failed, but it will not actively regulate apps that “pose a
low risk to patients.”172 However, the Final Guidance failed to ad-
dress the distinction between a mobile medical app that poses a low
risk (i.e., non-active FDA enforcement) and an app that poses a risk
to the patient’s safety (i.e., active FDA enforcement). Understand-
ing this distinction is essential for app developers to determine
whether an app in the idea-stage may come under future FDA
regulation.
To clarify this distinction, Appendix B in the Final Guidance in-
cludes approximately twenty examples of applications that qualify
as medical devices, but which the FDA does not intend to actively
regulate.173 For example, the FDA will not actively regulate “mobile
apps that help asthmatics track inhaler usage, asthma episodes ex-
perienced, location of user at the time of an attack, or
environmental triggers of asthma attacks.”174 While helpful, the
small quantity of examples offers limited help and will only be less
helpful going forward, as apps constantly evolve.
The ultimate ability of the Final Guidance to properly balance
innovation and safety will depend on the clarity of the distinction
169. Robert Lowes, FDA to Regulate Only ‘Small Subset’ of Mobile Medical Apps, MEDSCAPE
(Sept. 23, 2013), http://www.medscape.com/viewarticle/811519.
170. Xavier E. Martinez, 7 Best FDA Approved Health Apps, POWER YOUR PRACTICE, http://
www.poweryourpractice.com/medical-technology-trends/7-best-fda-approved-health-apps/
(last visited Apr. 11, 2015).
171. See, e.g., Eric Wicklund, FDA Gets Thumbs Up on Mobile Apps Regs, HEALTHCARE IT
NEWS (Sept. 24, 2013), http://www.healthcareitnews.com/category/city/washington-dc
(“mHealth advocates are giving good early reviews to the U.S. Food and Drug Administra-
tion’s final guidance document on the regulation of mobile medical apps, with one expert
calling it ‘an expansive document that truly seeks to deregulate our nimble and innovative
industry, while ensuring patient safety.’ ”).
172. FINAL GUIDANCE, supra note 11, at 13, 16.
173. See id. at 23–25.
174. Id. at 23.
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between an app that presents a risk and a low risk. Currently, this is a
difficult proposition, as a single application can be used in a variety
of ways. For example, as a commentator observed, “a scale that dis-
plays an individual’s weight has an extremely low inherent risk if
the individual is merely using the data for personal wellness pur-
poses, yet the same display of the same data may have a moderate
or high inherent risk if the patient is required to notify a healthcare
provider when their weight reaches a certain point.”175 Ultimately,
idea-stage innovators must be able to confidently predict the risk
classification of an application in order to assess its economic
feasibility.
IV. THE PROPOSED REFORM
At this stage, the risk-based regulatory scheme presents unavoida-
ble ambiguities. The mobile health application market appeared
and took-off almost overnight, and will continue to evolve at an
unimaginable pace. Applications advanced significantly from those
available just a few years ago: for example, compare the Doctor-
Calc’s Medical Calculator, which provides users with hundreds of
clinical equations such as Body Mass Index (BMI) and weight con-
versions,176 with Philips’ COPD application, which transmits the
user’s heart rhythm from a patch to their iPhone and then instantly
uploads the data to a cloud-based healthcare data management hub
for the user’s doctor.177 In all likelihood, the capabilities of mobile
medical apps today will pale in comparison to apps developed only
a few years from now.
To catch and keep up with this rapidly evolving market, the FDA
must engage with developers in the mobile application market. To
do this, and to bolster its 2013 Final Guidance, the FDA should (1)
transform the FDA’s little-used section 513(g) Request Program
into a mandatory pre-market notification program for all mobile
health applications and (2) use these pre-market notifications to
create a public database for the FDA to post enforcement determi-
nations. This database would then both serve as an expansive list of
175. BRADLEY MERRILL THOMPSON ET AL., MHEALTH REGULATORY COALITION, A CALL FOR
CLARITY: OPEN QUESTIONS ON THE SCOPE OF FDA REGULATION OF MHEALTH 38 (2010), availa-
ble at http://mhealthregulatorycoalition.org/wp-content/uploads/2010/12/mrcwhitefinal
122210.pdf.
176. See Medical Calculator, ITUNES, https://itunes.apple.com/app/medical-calculator/
id288555653?mt=8 (last visited Oct. 13, 2014).
177. See David Kender, Philips Gives COPD Patients a Lifeline with New Gadget, USA TODAY
(Oct. 13, 2014), http://www.usatoday.com/story/tech/2014/10/13/philips-gives-copd-pa-
tients-a-lifeline-with-new-gadget/17171535/.
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examples for developers to identify apps the FDA has declined to
actively regulate and allow doctors to publish feedback on mobile
applications. This Part will outline the proposal and explain how
such reform will allow the FDA to successfully implement its Final
Guidance, and simultaneously avoid increased regulation.
A. First Prong: Pre-market Notification Program
The first prong of this reform—the requirement for all mobile
health application developers to submit pre-market notification to
the FDA—alters a seldom-used option available to mobile health
app developers. Under section 513(g) of the FDCA,178 medical de-
vice manufacturers can receive feedback from the FDA regarding
the classification and regulatory requirements that may apply to
their proposed medical device. That provision states:
Within sixty days of the receipt of a written request of any per-
son for information respecting the class in which a device has
been classified or the requirements applicable to a device
under this [Act], the Secretary shall provide such a person a
written statement of the classification (if any) of such device
and the requirements of this [Act] applicable to the device.179
The pre-market notification program would transform this volun-
tary program into a mandatory pre-market notification program,
but remove the requirement that the FDA respond to every submis-
sion. Before a developer markets any mobile medical application,180
he would need to submit a section 513(g) request.181
The pre-market notification program is not the same as pre-mar-
ket approval. Pre-market approval is a formal determination by the
FDA of the safety and effectiveness of an application.182 This is a
178. See 21 U.S.C. § 360c(g) (2012).
179. Id.
180. The exact determination of when an application becomes a mobile health applica-
tion versus mobile medical application is uncertain. The FDA can work with industry to
determine where this dividing line should be.
181. The submission must include (a) a cover letter, (b) a description of the app, (c) a
description of what the app is to be used for, and (d) any proposed labeling or promotional
material for the app and, as applicable, any labeling or promotional material of a similar,
legally marketed app, if available. See FDA AND INDUSTRY PROCEDURES FOR 513(G) REQUESTS
FOR INFORMATION UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT, U.S. FOOD & DRUG
ADMIN. 8 (Apr. 6, 2012).
182. See Premarket Approval (PMA), U.S. FOOD & DRUG ADMIN. (Aug. 19, 2014), http://
www.fda.gov/Medicaldevices/Deviceregulationandguidance/Howtomarketyourdevice/Pre
marketsubmissions/Premarketapprovalpma/Default.htm.
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very expensive and slow process.183 Rather, the pre-market notifica-
tion program would provide the FDA with a quick, informal first
look at mobile health applications before developers begin to mar-
ket them.184 Within sixty days, the FDA would provide two responses
to the application innovator. First, the FDA would determine if the
application qualifies as a medical device. Over time it would be-
come more obvious which applications qualify as medical devices,
and the overwhelming majority of responses would therefore be
“yes.” Second, the FDA would determine whether it intends to ac-
tively regulate the specific application. If the Agency determines
that it would decline to actively regulate the application, then the
innovator would have fulfilled his FDA reporting obligations (as
long as no alterations take place). If the Agency decides to actively
regulate the application, then the FDA would help guide the inno-
vator through the next step: classifying the app as a Class I, II, or III
device.
The FDA will better protect patients from unsafe applications by
transforming the voluntary pre-market notification program into a
mandatory program for mobile applications. First, the pre-market
notification will allow the FDA to effectively implement the risk-
based enforcement discretion announced in the 2013 Final Gui-
dance. The risk-based system intends to balance innovation and
patient safety;185 however, as discussed above, the FDA did not
clearly define and distinguish app characteristics that present “a
risk” or a “low risk.”186 This lack of clarity makes applying the system
extremely challenging, if not impossible, in an industry that “is con-
stantly evolving and requires the FDA to continually balance
interests of patient safety and technological innovation in its regula-
tion of these devices.”187 In the two years after the issuance of the
Draft Guidance, the FDA attempted to clearly define this distinc-
tion, and in the Final Guidance the Agency only provided current
examples as guideposts for future innovators. As this technology de-
velops, these guideposts will become outdated and thus cease to be
useful. The FDA must fully understand the entire mobile health
application landscape to reset and evolve these guideposts. The pre-
183. See id.
184. For this proposal, the exact determination of when an application becomes a mobile
health application (does not require pre-market notification) versus a mobile medical appli-
cation (requires pre-market notification) is uncertain and would be a question for future
research.
185. See, e.g., Rosen, supra note 156 (“The FDA intends that Apps falling into this category
will be subject to the same risk-based approach used by the agency to assess and regulate
traditional medical devices.”).
186. See supra discussion at Part III.B.iii.
187. Onel, supra note 144, at *11.
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market notification program would force the industry to educate
the FDA on this new, ever-evolving market.
Second, the FDA would take an active role in assisting app devel-
opers as they navigate the FDCA requirements. The question facing
the vast majority of app developers in the early stage is not whether
their app will qualify as a medical device,188 but rather whether the
FDA will use enforcement discretion or classify the app as a Class I,
II, or III device. This presents a challenging inquiry for developers,
which becomes more complicated because most app developers are
not repeat players in the FDA’s regulatory world. Confronting
Agency oversight, particularly in this context, promises a new and
challenging experience.189 First-time innovators may not even think
that their application behooves direct FDA regulation, or they may
find the process intimidating and opt to abandon development of a
new app.190 To help alleviate this confusion, the pre-market notifi-
cation program would provide a process for the FDA to assist
application developers determine which regulatory requirements
apply to their applications.
Likewise, the pre-market notification program would support the
FDA’s preference to educate and work with app developers—many
of whom have never worked with the FDA—rather than take puni-
tive enforcement action against many applications.191 As discussed
above, the FDA used a tempered approach with Biosense Technolo-
gies and its urinalysis app uCheck.192 Rather than send a warning
letter—the traditional FDA response to notify a company that the
agency “considers one or more products . . . to be in violation of the
[FDCA]”193—the FDA “exercised notable restraint by sending an ‘It
Has Come to Our Attention Letter.’”194 Subsequently, the FDA
188. See supra Part I.B. (explaining that the vast majority of mobile health applications
qualify as medical devices subject to FDA regulatory enforcement).
189. See Chris Wiltz, FDA’s Regulation of Mobile Medical Apps Will Probably Confuse You, MEDI-
CAL DEVICE AND DIAGNOSTIC INDUSTRY (May 30, 2013), http://www.mddionline.com/blog/
devicetalk/fdas-regulation-mobile-medical-apps-will-probably-confuse-you.
190. See, e.g., Andrew Litt, When is a Mobile App a Medical Device? The Future of Healthcare
May Depend on the Answer, COMPUTERWORLD (Mar. 26, 2014), http://www.computerworld
.com/article/2476087/healthcare-it/when-is-a-mobile-app-a-medical-device—the-future-of-
healthcare-may-depend-on-the-answ.html (“Others (including some members of Congress)
see this gray area as just the kind of ambiguity and uncertainty that will discourage
innovation.”).
191. Mobile Medical Apps Guidance, DUANE MORRIS LLP (Oct. 4, 2013), http://www.duane
morris.com/alerts/mobile_medical_apps_guidance_5037.html.
192. See supra note 145 and accompanying text.
193. See U.S. FOOD & DRUG ADMIN., supra note 143.
194. Onel, supra note 144.
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opened a line of communication with Biosense to discuss the evolv-
ing regulatory status of uChek and other related applications.195
The pre-market notification program would similarly open dia-
logue between the FDA and industry to the benefit of both sides.
The current FDA process for the approval of traditional medical
devices sharply contrasts with the lack of information available for
prospective mobile application developers. In the early stages of de-
velopment, a prospective traditional device developer can use nine
databases to quickly determine their device’s classification, includ-
ing a CDRH tool titled “Classify Your Medical Device.”196 For
mobile app developers, these tools are virtually nonexistent.197
Commentators have complained that the publicly available “510(k)
summaries” for the apps that the Agency has approved provide “lit-
tle information of practical use for developing a comprehensive
data package to support clearance of a later [filing].”198 Further,
even if an app maker can determine with confidence what device
classification covers its app, it will still face a significant challenge in
determining what data it will need to submit to support a marketing
filing.199 The FDA maintains hundreds of device-specific guidelines
to help traditional device developers determine the proper data de-
velopment necessary to support their submissions.200 Conversely,
beyond the Final Guidance, there are no device-specific guidelines
for mobile apps.
Critics might claim that pre-market notification should remain
voluntary, as it is currently constructed under section 513(g), be-
cause any increase in the FDA’s involvement could stymie app
development.201 Regulatory hurdles—and potentially costly ones at
that—may dissuade developers from pursuing new applications.202
However, this result is unlikely. One of the major benefits of this
program to developers, educating the FDA, depends on developers
195. Darius Tahir, Biosense Modifies Urinalysis App To Comply With FDA, “THE GRAY SHEET,”
Jul. 22, 2103, at 11.
196. See Classify Your Medical Device, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/medi-
caldevices/deviceregulationandguidance/overview/classifyyourdevice/default.htm (last
updated July 29, 2014).
197. Mobile Medical Apps Guidance, supra note 191.
198. Id.
199. Id. (“However, app makers should understand that the guidance does not provide
any advice on the specific information and data that an app maker will need to develop and,
in many cases, submit to [the] FDA.”)
200. Id.; see generally REGULATORY INFORMATION, U.S. FOOD & DRUG ADMIN., http://www
.fda.gov/RegulatoryInformation/Guidances/default.htm (last visited Mar. 20, 2015) (con-
taining links to thousands of FDA guidances).
201. See Onel, supra note 144.
202. See id.
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using the program, and would encourage rather than dampen in-
novation and entrepreneurialism. Currently, very few medical
device developers opt to use the voluntary program, which costs the
applicant $2,900.203 For mobile application developers, only highly
cautious, responsible parties with deep pockets will utilize this tool.
Irresponsible developers—who are of the most concern to the
FDA—are the least likely to opt into the voluntary section 513(g)
program. This internal contradiction exposes the inadequacy of the
current program; it merely sets the FDA’s mind at ease and does
not actually protect the public from harm.
Furthermore, regulatory certainty serves as a critical condition
for innovation.204 As one legal commentator noted: “Confusion
around whether a particular app will be regulated is simply sand in
the gears of commerce, keeping the software development machine
from reaching its full potential.”205 In February 2014, at the direc-
tion of Congress, the FDA organized a working group to discuss the
2013 Final Guidance.206 The 29-person working group was geo-
graphically diverse and included patients, doctors, innovators,
venture capital investors, and healthcare third-party payers.207 In its
final analysis, the group’s suggested improvements called for the
FDA “doing a better job of explaining the existing legal require-
ments.”208 As one commentator put it, “[t]he problem isn’t the
[FDCA].”209 The group pointed to the FDA and to its enforcement
decisions, as the most qualified actor to determine the nuances of
the mobile application market.210 As the same commentator noted:
“The devil is in the details, and innovators need those details to be
203. GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF – USER FEES FOR
513(G) REQUESTS FOR INFORMATION, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Regu-
latoryInformation/Guidances/ucm209852.htm (last visited Mar. 20, 2015). Determining the
proper cost of this program is outside the scope of this article. However, the app manufactur-
ers’ costs are not expected to be significant. By making the program mandatory, the
overhead costs will be spread among many manufacturers. Additionally, the costs will likely
be passed on to consumers, further diluting the manufacturer’s expense.
204. See Chris Pruitt, Mobile Medical Apps: What Will Future FDA Regulation Look Like? INSIDE
MED. DEVICES (Nov. 14, 2012), http://www.insidemedicaldevices.com/2012/11/14/fda-regu-
lation-of-mobile-medical-apps-what-does-the-future-hold/ (“This uncertainty has caused
many app developers to struggle with the questions of whether their apps are subject to
regulation and, if so, what requirements would apply.”).
205. Bradley Merrill Thompson, How the FDA Can Improve Regulation of Mobile Health, Ac-
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able to make business decisions. One of the biggest challenges that
innovators have in this space is the presently opaque regulatory sys-
tem.”211 As a result of the group’s conclusions, on March 19, 2014, a
bipartisan group of senators sent a letter to the FDA, urging the
FDA to further clarify its Final Guidance “to avoid stakeholder con-
fusion over how a wider range of medical software might be
appropriately regulated.”212 The pre-market notification program
will seek to resolve this lack of clarity and certainty surrounding
medical software regulation. Direct work with all developers, not
only the responsible ones that opt into the current voluntary pro-
gram, will allow the FDA to better understand mobile apps and
clearly define its regulatory scheme.
In the absence of further clarification, Congress could push
harder for a more extreme result–removing the FDA’s statutory au-
thority to regulate mobile medical applications. In February 2014,
Senator Marco Rubio introduced a bill titled The Preventing Regu-
latory Overreach to Enhance Care Technology (PROTECT) Act of
2014, which would amend section 201(h) of the FDCA to clarify
that the term “medical device” does not include clinical software or
health software such as mobile medical applications.213 Instead of
the FDA, the PROTECT Act would charge the National Institute of
Standards and Technology (NIST) with oversight over digital
health products. However, as one commentator noted, “[the] NIST
is not a regulatory body with the power to investigate wrongdoing. It
is a federal body that works with the industry to develop and apply
technology, measurements, and standards.”214
This “nuclear option” could have disastrous consequences for
the industry and consumers alike. Developers may need to comply
with new NIST standards.215 According to the same commentator,
“[i]n the past, [creating new standards] has entrenched the incum-
bents but hindered startups, as this certification process costs a lot
211. Id.
212. Press Release, Senate Comm. on Health, Educ., Labor & Pensions, Senators Urge
Further Clarity and Transparency from FDA on Medical Mobile Apps, (Mar. 19, 2014), avail-
able at http://www.help.senate.gov/newsroom/press/release/?id=2354f485-f387-40c4-80c9-
158491f2fd1a; see also Thompson, supra note 204 (“[The] FDA needs to do a better job at a
very granular level of explaining what types of software the agency regulates and what types it
doesn’t.”).
213. Nita Farahany, Reining in FDA Regulation of Mobile Health Apps, WASH. POST (Mar. 25,
2014), http://www.washingtonpost.com/news/olokh-conspiracy/wp/2014/03/25/reining-
in-fda-regulation-of-mobile-health-apps/.
214. Farr, supra note 17.
215. Id.
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of money.”216 The strongest lobbyists, representing the largest de-
velopers, would push for incumbent-friendly regulations.217 Bradley
Merrill Thompson, a Washington, D.C.-based attorney who advises
the FDA on this subject, calls the proposed bill a “meat cleaver” that
would do a lot of damage to the regulation of mobile medical appli-
cations.218 He asserts that the PROTECT Act “is a colossally bad
idea, both for patients who would be put at risk, but also for [an]
industry that would be dragged down by apps that don’t work and
destroy the credibility for the industry.”219 Thus, this nuclear option
should be avoided at all costs. The pre-market notification system
may sufficiently convince members of Congress that they do not
need to enact such an extreme bill, as increased industry-agency
dialogue would further cement the FDA’s legitimacy in regulating
mobile medical applications.
B. Second Prong: Mobile Medical Application Database
The second prong of this reform—establishing a public database
for the FDA to disclose its enforcement discretion determinations
and for doctors to provide feedback on mobile applications—would
be an important step to ensure post-market surveillance of mobile
medical applications. The second prong does not provide a substi-
tute for the first prong, but rather it depends on the first prong.
The breadth and usefulness of the database would rely on an FDA
mandate that requires all mobile health app developers to submit a
pre-market notification. Additionally, the database would allow phy-
sicians and users to submit adverse events to the FDA. Importantly,
this public database would increase physicians’—and subsequently
patients’—trust in mobile medical applications as a safe and effec-
tive healthcare tool. A recent poll of 250 doctors found that forty-
two percent will not prescribe mobile apps to patients because of
the lack of regulatory oversight.220 The database could alleviate this
unease.
Post-market surveillance would increase physician faith in mobile
apps for two reasons: first, it would help ensure the FDA learns of
216. Id.
217. Id.; How long it takes the FDA to “approve” a 510(k) submission, EMERGO, http://www
.emergogroup.com/resources/research/fda-510k-review-times-research (last visited Mar. 20,
2015).
218. Eric Wicklund, Opponents say PROTECT Act Could Destroy mHealth, Endanger Patients,
MHEALTHNEWS (Feb. 17, 2014), http://www.mhealthnews.com/news/opponents-protect-act-
destroy-mhealth-endanger-patients-mobile-FDA.
219. Id.
220. See Thompson, supra note 204.
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faulty apps, even if the risk only becomes apparent after market
entry. The FDA observed this trend in reports about adverse events
associated with pharmaceutical drugs: “unexpected and sometimes
serious safety problems can emerge once a product goes to market
and is used by millions of people.”221 This concern may be exacer-
bated for mobile medical apps, where the FDA emphasizes a light
pre-market regulatory touch, as compared to the heavy pre-market
regulation of drugs.222 Second, a risk-based regulatory scheme ne-
cessitates an adaptive risk analysis. Mobile technology and app
development are constantly changing. “What stands today could
change tomorrow.”223 The mobile medical apps available in 2008
look very different from the apps available in 2014. And the same
will be true in 2020. As a result, for the FDA to maintain a risk-based
regulatory scheme, it must receive user input to adjust its pre-mar-
ket risk analysis as new technology develops. The FDA’s pre-market
risk analysis is prospective, based on existing technology. Thus, user
data—and the subsequent recalibration of mobile app risk analy-
sis—are necessary if the FDA intends to conduct effective risk
analysis and properly protect consumers from unsafe mobile apps.
Creating an FDA public database is not a novel idea. For post-
marketing safety surveillance of all approved drug and therapeutic
biologic products, the Center for Drug Evaluation and Research
(CDER)224 maintains the FDA Adverse Event Reporting System
(FAERS).225 This computerized information database allows physi-
cians and consumers alike to voluntarily report any adverse events
and medication errors that might occur with these marketed prod-
ucts.226 FAERS empowers the FDA to monitor new safety concerns
related to a marketed product, evaluate a manufacturer’s compli-
ance with reporting regulations, and respond to outside requests
221. The Public’s Stake in Adverse Event Reporting, U.S. FOOD & DRUG ADMIN (Aug. 20,
2009), http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveil-
lance/AdverseDrugEffects/ucm179586.htm.
222. See Premarket Approval, supra note 182 (describing the onerous pre-market approval
process for pharmaceutical drugs).
223. Brian Dolan, In Tense Hearing, Congressman Declares “Software is not a Medical Device,”
MOBI HEALTH NEWS (Nov. 21, 2013), http://mobihealthnews.com/27563/in-tense-hearing-
congressman-declares-software-is-not-a-medical-device/.
224. CDER is a division of the FDA that monitors most drugs as defined in the FDCA. See
About the Center for Drug Evaluation and Research, U.S. FOOD & DRUG ADMIN. (Dec. 9, 2014),
http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/de-
fault.htm.
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for information.227 The results of this infrastructure can be power-
ful: voluntary reports of severe and sometimes fatal conditions led
to the market removal of the nonsteroidal anti-inflammatory drug
Duract (bromfenac) in 1998 and the antibiotic Zyvox (linezolid) in
2000, both within months of the drugs’ market approvals.228 As the
FDA put it, “the bottom line: voluntary and mandatory reporting
plays an important role in the FDA’s postmarket safety
monitoring.”229
Moreover, this database would help early-stage innovators to
quickly ascertain how their app may be classified before they submit
a pre-market notification. As described above, currently there are
no resources available for entrepreneurs to proactively educate
themselves on potential regulatory requirements.230 As one entre-
preneur put it, “[q]uite bluntly [the FDA] need[s] to be more
entrepreneur friendly.”231 Sophisticated mobile medical app devel-
opment requires investment. In a pitch to a venture capitalist, the
innovator must be able to project whether or not the FDA will regu-
late the app, as this can dramatically affect the necessary investment
and extend associated timelines.232 The mobile medical app
database would contain robust data on how the FDA has ap-
proached previous applications, thereby helping innovators
anticipate potential regulatory obligations. A mobile medical app
database would provide app developers with an equivalent tool to
what the FDA already provides traditional medical device
developers.
CONCLUSION
Creating and maintaining a regulatory scheme that protects the
public from unsafe mobile medical applications and simultaneously
promotes innovation is a significant undertaking. Although the
FDA’s 2013 Final Guidance is a positive first step towards regulating
mobile medical applications, the FDA needs to do more. As the
technology continues to develop, the FDA must continue to work
directly with all actors—including innovators, doctors, and pa-
tients—to keep pace. To assist in this effort, the FDA should adopt
a pre-market notification program and mobile medical application
227. Id.
228. See The Public’s Stake in Adverse Event Reporting, supra note 221.
229. Id.
230. See supra notes 186–88 and accompanying text.
231. See Thompson, supra note 205.
232. Id.
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database. This Note recommends two interrelated solutions to help
the FDA keep its finger on the pulse of the mobile medical applica-
tion market, while not stymieing growth and development. The
FDA will, thus, ensure that this burgeoning market can reach its
peak potential.
